Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610

[1]  A. Dicker,et al.  Vascular endothelial growth factor (VEGF) expression in locally advanced prostate cancer: secondary analysis of radiation therapy oncology group (RTOG) 8610 , 2013, Radiation Oncology.

[2]  K. Jennbacken,et al.  Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang‐2 , 2012, The Prostate.

[3]  S. Groshen,et al.  The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes , 2010, The Prostate.

[4]  J. Concato,et al.  Molecular Markers and Death From Prostate Cancer , 2009, Annals of Internal Medicine.

[5]  E. D. de Vries,et al.  Prognostic versus predictive value of biomarkers in oncology. , 2008, European journal of cancer.

[6]  C. Ménard,et al.  Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials , 2008, Cancer and Metastasis Reviews.

[7]  Matthew Sydes,et al.  Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. , 2008, The Lancet. Oncology.

[8]  D. Grignon,et al.  Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Camparo,et al.  The expression of vascular endothelial growth factor is associated with the risk of cancer progression after radical prostatectomy , 2007, BJU international.

[10]  Jeffrey K. Cohen,et al.  Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. , 2007, American journal of clinical pathology.

[11]  P. Chieffi,et al.  The endocrine-gland-derived vascular endothelial growth factor (EG-VEGF)/prokineticin 1 and 2 and receptor expression in human prostate: Up-regulation of EG-VEGF/prokineticin 1 with malignancy. , 2006, Endocrinology.

[12]  T. McDonnell,et al.  Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10. , 2006, International journal of radiation oncology, biology, physics.

[13]  A. Dennison,et al.  HYPOXIA AND ANGIOGENESIS IN PANCREATIC CANCER , 2006, ANZ journal of surgery.

[14]  F. Rojo,et al.  Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. , 2006, Histology and histopathology.

[15]  N. Dhalla,et al.  Angiogenesis--a new target for future therapy. , 2006, Vascular pharmacology.

[16]  A. Markoe,et al.  Influence of Number of CAG Repeats on Local Control in the RTOG 86-10 Protocol , 2006, American journal of clinical oncology.

[17]  J. Harmey,et al.  Angiogenic and cell survival functions of Vascular Endothelial Growth Factor (VEGF) , 2005, Journal of cellular and molecular medicine.

[18]  D. Grignon,et al.  MDM2 as a predictor of prostate carcinoma outcome , 2005, Cancer.

[19]  James A Hanley,et al.  20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.

[20]  D. Grignon,et al.  Ki-67 Staining Index Predicts Distant Metastasis and Survival in Locally Advanced Prostate Cancer Treated With Radiotherapy , 2004, Clinical Cancer Research.

[21]  M. Dickler,et al.  Maximizing the potential of bevacizumab in cancer treatment. , 2004, The oncologist.

[22]  T. Wheeler,et al.  Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  G. Landberg,et al.  Expression of vascular endothelial growth factor protein in human renal cell carcinoma , 2004, BJU international.

[24]  P. Okunieff,et al.  Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Kantoff,et al.  Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Grignon,et al.  Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  E. Voest,et al.  Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches , 2002, Molecular and Cellular Endocrinology.

[28]  L. Bégin,et al.  Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis , 2002, Molecular and Cellular Endocrinology.

[29]  C. Kwak,et al.  Thrombospondin‐1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia , 2002, BJU international.

[30]  J. Köllermann,et al.  Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. , 2001, American journal of clinical pathology.

[31]  S. Loening,et al.  Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer , 2000, The Prostate.

[32]  R. Montironi,et al.  Vascular endothelial growth factor expression and capillary architecture in high‐grade PIN and prostate cancer in untreated and androgen‐ablated patients , 2000, The Prostate.

[33]  J. Overgaard,et al.  Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[34]  G. Mcmahon,et al.  VEGF receptor signaling in tumor angiogenesis. , 2000, The oncologist.

[35]  A. Harris.  von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy. , 2000, The oncologist.

[36]  V. Laudone,et al.  Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cells. , 1997, The Journal of urology.

[37]  W. Tilley,et al.  Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. , 1997, The Journal of urology.

[38]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[39]  D. Grignon,et al.  p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. , 1997, Journal of the National Cancer Institute.

[40]  N. Hayashi,et al.  Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. , 1996, Cancer research.

[41]  E. Manseau,et al.  Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. , 1993, The American journal of pathology.

[42]  M. Steiner.  Role of peptide growth factors in the prostate: a review. , 1993, Urology.

[43]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[44]  N. Ferrara,et al.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. , 1989, Biochemical and biophysical research communications.

[45]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[46]  A Böcking,et al.  Histologic grading of prostatic carcinoma. , 1980, Pathology, research and practice.

[47]  W. Hellstrom,et al.  J Urol , 2014 .

[48]  N. Clarke,et al.  Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. , 2009, Health technology assessment.

[49]  R Garside,et al.  The harmful health effects of recreational ecstasy: a systematic review of observational evidence. , 2009, Health technology assessment.

[50]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[51]  D. Hopster,et al.  Distribution of vascular endothelial growth factor (VEGF) in prostate disease , 2002, Prostate Cancer and Prostatic Diseases.

[52]  S. Loening,et al.  Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer , 2000, The Prostate.

[53]  P. Walsh,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. , 1997, The Journal of urology.

[54]  Anthony J. Guidi,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. , 1995, Human pathology.

[55]  W. Reinhold,et al.  Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. , 1993, The Journal of clinical investigation.